DK0495896T3 - Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel - Google Patents

Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel

Info

Publication number
DK0495896T3
DK0495896T3 DK90915992.3T DK90915992T DK0495896T3 DK 0495896 T3 DK0495896 T3 DK 0495896T3 DK 90915992 T DK90915992 T DK 90915992T DK 0495896 T3 DK0495896 T3 DK 0495896T3
Authority
DK
Denmark
Prior art keywords
hiv
infections
protection against
vaccine
preparation
Prior art date
Application number
DK90915992.3T
Other languages
Danish (da)
English (en)
Inventor
Ursula Dietrich
Michalina Adamski
Hagen Von Briesen
Herbert Kuehnel
Helga Ruebsamen-Waigmann
Original Assignee
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6391493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0495896(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Application granted granted Critical
Publication of DK0495896T3 publication Critical patent/DK0495896T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK90915992.3T 1989-10-14 1990-10-12 Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel DK0495896T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3934366A DE3934366A1 (de) 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum

Publications (1)

Publication Number Publication Date
DK0495896T3 true DK0495896T3 (da) 1994-10-10

Family

ID=6391493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90915992.3T DK0495896T3 (da) 1989-10-14 1990-10-12 Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel

Country Status (8)

Country Link
US (1) US5861243A (https=)
EP (1) EP0495896B1 (https=)
JP (1) JP3152433B2 (https=)
AT (1) ATE106748T1 (https=)
DE (2) DE3934366A1 (https=)
DK (1) DK0495896T3 (https=)
ES (1) ES2055922T3 (https=)
WO (1) WO1991005567A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
CN1651457B (zh) * 1994-10-20 2010-07-28 巴斯德研究所 Hiv-1 o组(或亚组)逆转录病毒抗原的核苷酸序列
US6124262A (en) * 1995-03-17 2000-09-26 The Regents Of The University Of California Compositions and methods for reducing adhesiveness of defective red blood cells
US6426412B1 (en) * 1995-12-20 2002-07-30 Subsidiary No. 3, Inc. Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
WO1998041657A1 (en) * 1997-03-20 1998-09-24 Affymetrix, Inc. Iterative resequencing
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
ID30407A (id) 1999-05-13 2001-11-29 American Cyanamid Co Formulasi-formulasi kombinasi bahan penambah
AU784679B2 (en) * 1999-12-23 2006-05-25 International Aids Vaccine Initiative Improvements in or relating to immune responses to HIV
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
HUP0600589A2 (en) * 2000-11-10 2006-11-28 Wyeth Corp Adjuvant combination formulations
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
US7563437B2 (en) 2005-02-15 2009-07-21 Thymon, Llc Methods and compositions for impairing multiplication of HIV-1
US20100275278A1 (en) * 2006-02-03 2010-10-28 Karp Nelson M Animal model for hiv induced disease
WO2009155489A2 (en) 2008-06-19 2009-12-23 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN115124628B (zh) * 2021-03-27 2023-03-31 中国科学院昆明植物研究所 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU608294B2 (en) * 1987-01-16 1991-03-28 Institut Pasteur Peptides having immunological properties 2-hiv-2
CA1340747C (en) * 1988-06-14 1999-09-14 Karsten Henco Hiv-2 virus variants

Also Published As

Publication number Publication date
JP3152433B2 (ja) 2001-04-03
WO1991005567A1 (de) 1991-05-02
ES2055922T3 (es) 1994-09-01
DE3934366C2 (https=) 1991-11-07
JPH05505389A (ja) 1993-08-12
DE59006080D1 (de) 1994-07-14
EP0495896B1 (de) 1994-06-08
US5861243A (en) 1999-01-19
ATE106748T1 (de) 1994-06-15
DE3934366A1 (de) 1991-04-18
EP0495896A1 (de) 1992-07-29

Similar Documents

Publication Publication Date Title
DK0495896T3 (da) Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel
ATE135747T1 (de) Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
ATE252640T1 (de) Verbindungen zur immunotherapie und diagnose von tuberkulose
CA2596274A1 (en) Recombinant mva virus, and the use thereof
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
EP0232798A3 (en) Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
DK694687D0 (da) Hidtil ukendte oligosaccharider, immunogener og vacciner og fremgangsmaader til fremstilling af disseoligosaccharider, immunogener og vacciner
GR3022248T3 (en) Oligonucleotide sequences for amplification of type HIV-2 and SIV retroviruses genomes and their application to in-vitro diagnostic of infections caused by these viruses
HUP0303431A2 (hu) PRRS vírus élő legyengített törzsei
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
BR9608894A (pt) Produtos extracelulares abundantes e processos para suas producões e usos
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
ES379641A1 (es) Procedimiento de produccion de antigenos inactivos para preparados farmaceuticos.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
NO890565D0 (no) Forhindring og behandling av retroviral sykdom.
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
DK612889D0 (da) Enzym og fremgangsmaade til fremstilling deraf
CA2350127A1 (en) Avipox vector coding an hiv antigen and a cytokine
ATE143373T1 (de) Proteine, vakzine und nucleinsäuren
WO2003073984A3 (en) Tat as an immunogen
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
TH23870A (th) วัคซีนและวิธีสำหรับการเตรียม